Meridian Investment Counsel Inc. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,847 shares of the biopharmaceutical company’s stock after acquiring an additional 2,746 shares during the period. Meridian Investment Counsel Inc.’s holdings in Gilead Sciences were worth $1,546,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of GILD. Penserra Capital Management LLC grew its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares in the last quarter. American Beacon Advisors Inc. acquired a new position in shares of Gilead Sciences in the first quarter worth $143,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 480 shares in the last quarter. Capstone Investment Advisors Netherlands B.V. acquired a new position in shares of Gilead Sciences during the second quarter worth $172,000. Finally, Sterling Investment Advisors Ltd. acquired a new position in shares of Gilead Sciences during the second quarter worth $184,000. Institutional investors and hedge funds own 76.23% of the company’s stock.

In other news, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock valued at $37,404,139 in the last 90 days. 1.30% of the stock is currently owned by insiders.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $73.29 on Thursday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The stock has a market cap of $95,736.46, a price-to-earnings ratio of 7.65, a price-to-earnings-growth ratio of -1.23 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the prior year, the firm posted $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. equities research analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.84%. Gilead Sciences’s dividend payout ratio is presently 23.69%.

A number of equities analysts recently commented on the stock. Leerink Swann boosted their target price on shares of Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research note on Thursday, October 19th. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Berenberg Bank reiterated a “buy” rating and set a $86.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $85.22.

TRADEMARK VIOLATION NOTICE: “Meridian Investment Counsel Inc. Boosts Holdings in Gilead Sciences, Inc. (GILD)” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2017/12/07/meridian-investment-counsel-inc-boosts-holdings-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.